Sign In
Buy KE
Kimball Electronics Earnings Calls
| Release date | May 05, 2026 |
| EPS estimate | $0.380 |
| EPS actual | $0.330 |
| EPS Surprise | -13.16% |
| Revenue estimate | 356.274M |
| Revenue actual | 352.922M |
| Revenue Surprise | -0.94% |
| Release date | Feb 04, 2026 |
| EPS estimate | $0.280 |
| EPS actual | $0.280 |
| Revenue estimate | 339.344M |
| Revenue actual | 341.28M |
| Revenue Surprise | 0.571% |
| Release date | Nov 05, 2025 |
| EPS estimate | $0.240 |
| EPS actual | $0.490 |
| EPS Surprise | 104.17% |
| Revenue estimate | 342.981M |
| Revenue actual | 365.603M |
| Revenue Surprise | 6.60% |
| Release date | Aug 13, 2025 |
| EPS estimate | $0.200 |
| EPS actual | $0.340 |
| EPS Surprise | 70.00% |
| Revenue estimate | 337.486M |
| Revenue actual | 380.472M |
| Revenue Surprise | 12.74% |
Last 4 Quarters for Kimball Electronics
Below you can see how KE performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 13, 2025 |
| Price on release | $20.97 |
| EPS estimate | $0.200 |
| EPS actual | $0.340 |
| EPS surprise | 70.00% |
| Date | Price |
|---|---|
| Aug 07, 2025 | $19.49 |
| Aug 08, 2025 | $19.92 |
| Aug 11, 2025 | $19.74 |
| Aug 12, 2025 | $20.83 |
| Aug 13, 2025 | $20.97 |
| Aug 14, 2025 | $24.71 |
| Aug 15, 2025 | $25.82 |
| Aug 18, 2025 | $27.25 |
| Aug 19, 2025 | $27.18 |
| 4 days before | 7.59% |
| 4 days after | 29.61% |
| On release day | 17.84% |
| Change in period | 39.46% |
| Release date | Nov 05, 2025 |
| Price on release | $30.38 |
| EPS estimate | $0.240 |
| EPS actual | $0.490 |
| EPS surprise | 104.17% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $29.25 |
| Oct 31, 2025 | $29.08 |
| Nov 03, 2025 | $29.09 |
| Nov 04, 2025 | $28.79 |
| Nov 05, 2025 | $30.38 |
| Nov 06, 2025 | $28.16 |
| Nov 07, 2025 | $27.23 |
| Nov 10, 2025 | $28.20 |
| Nov 11, 2025 | $27.91 |
| 4 days before | 3.86% |
| 4 days after | -8.13% |
| On release day | -7.31% |
| Change in period | -4.58% |
| Release date | Feb 04, 2026 |
| Price on release | $30.72 |
| EPS estimate | $0.280 |
| EPS actual | $0.280 |
| Date | Price |
|---|---|
| Jan 29, 2026 | $30.58 |
| Jan 30, 2026 | $30.21 |
| Feb 02, 2026 | $31.17 |
| Feb 03, 2026 | $31.06 |
| Feb 04, 2026 | $30.72 |
| Feb 05, 2026 | $23.55 |
| Feb 06, 2026 | $26.29 |
| Feb 09, 2026 | $25.59 |
| Feb 10, 2026 | $24.84 |
| 4 days before | 0.458% |
| 4 days after | -19.14% |
| On release day | -23.34% |
| Change in period | -18.77% |
| Release date | May 05, 2026 |
| Price on release | $27.15 |
| EPS estimate | $0.380 |
| EPS actual | $0.330 |
| EPS surprise | -13.16% |
| Date | Price |
|---|---|
| Apr 29, 2026 | $26.04 |
| Apr 30, 2026 | $27.01 |
| May 01, 2026 | $27.21 |
| May 04, 2026 | $26.88 |
| May 05, 2026 | $27.15 |
| May 06, 2026 | $25.16 |
| May 07, 2026 | $25.95 |
| May 08, 2026 | $26.14 |
| May 11, 2026 | $25.81 |
| 4 days before | 4.26% |
| 4 days after | -4.94% |
| On release day | -7.33% |
| Change in period | -0.88% |
Kimball Electronics Earnings Call Transcript Summary of Q1 2026
Kimball Electronics reported Q1 fiscal 2026 revenue of $365.6 million, down 2% year-over-year, driven by strong Medical growth (+13% to $102M) offset by declines in Automotive (-10% to $164M) and modest Industrial weakness (-1% to $100M). Gross margin expanded to 7.9% (up 160 bps) due to favorable mix, the Tampa facility closure, and restructuring. Adjusted operating income was $17.5M (4.8% of sales) and adjusted EPS was $0.49, roughly doubling year-over-year. Cash from operations was positive for the seventh consecutive quarter; cash was $75.7M and borrowings were $138M (down 44% YoY), with $370M of short-term liquidity available. Inventory decreased 19% YoY and cash conversion days improved to 83. Management reiterated fiscal 2026 guidance: sales $1.35B–$1.45B and adjusted operating income of 4.0%–4.25% of sales; capex expected $50M–$60M. Strategic priorities: continue scaling medical CMO capabilities (organic and targeted tuck-in M&A), leverage new Indianapolis facility and other medical sites, maintain disciplined capital allocation, and pursue further restructuring as needed. Management expects a return to profitable top-line growth in FY2027, with medical as the primary growth engine.
